Terms: = Kidney tumors AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Treatment
40 results:
1. Targeted drug-loaded PLGA-pcl microspheres for specific and localized treatment of triple negative breast cancer.
Nwazojie CC; Obayemi JD; Salifu AA; Borbor-Sawyer SM; Uzonwanne VO; Onyekanne CE; Akpan UM; Onwudiwe KC; Oparah JC; Odusanya OS; Soboyejo WO
J Mater Sci Mater Med; 2023 Aug; 34(8):41. PubMed ID: 37530973
[TBL] [Abstract] [Full Text] [Related]
2. ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma.
Wang H; Zhao J; He H; Xie X; Dai J; Xu D; Huang X
Biochem Biophys Res Commun; 2023 Sep; 671():255-262. PubMed ID: 37307709
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
4. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I; Billowria K; Kumar B; Chawla PA
Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
Liu S; Feng C; Liu C; Wang Z
Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
[TBL] [Abstract] [Full Text] [Related]
6. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract] [Full Text] [Related]
7. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
[TBL] [Abstract] [Full Text] [Related]
8. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.
Dumond A; Montemagno C; Vial V; Grépin R; Pagès G
Cells; 2021 May; 10(5):. PubMed ID: 34067671
[TBL] [Abstract] [Full Text] [Related]
9. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract] [Full Text] [Related]
10. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
[TBL] [Abstract] [Full Text] [Related]
11. Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy.
Zhang L; Zhang S; Li M; Li Y; Xiong H; Jiang D; Li L; Huang H; Kang Y; Pang J
Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():111956. PubMed ID: 33812584
[TBL] [Abstract] [Full Text] [Related]
12. Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo.
Engelberg S; Netzer E; Assaraf YG; Livney YD
Cell Death Dis; 2019 Sep; 10(10):702. PubMed ID: 31541073
[TBL] [Abstract] [Full Text] [Related]
13. Gradiently degraded electrospun polyester scaffolds with cytostatic for urothelial carcinoma therapy.
Wang J; Wang G; Shan H; Wang X; Wang C; Zhuang X; Ding J; Chen X
Biomater Sci; 2019 Feb; 7(3):963-974. PubMed ID: 30569055
[TBL] [Abstract] [Full Text] [Related]
14. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract] [Full Text] [Related]
15. VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.
Eronat O; Onursever A; Suren D; Yildirim M; Kandemir O; Ali Kahya H
J BUON; 2016; 21(5):1250-1258. PubMed ID: 27837630
[TBL] [Abstract] [Full Text] [Related]
16. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
17. vegfr3 and CD31 as prognostic factors in renal cell cancer.
Virman J; Bono P; Luukkaala T; Sunela K; Kujala P; Kellokumpu-Lehtinen PL
Anticancer Res; 2015 Feb; 35(2):921-7. PubMed ID: 25667475
[TBL] [Abstract] [Full Text] [Related]
18. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
[TBL] [Abstract] [Full Text] [Related]
19. Minimally invasive nephrectomy for Wilms tumors in children - data from SIOP 2001.
Warmann SW; Godzinski J; van Tinteren H; Heij H; Powis M; Sandstedt B; Graf N; Fuchs J;
J Pediatr Surg; 2014 Nov; 49(11):1544-8. PubMed ID: 25475791
[TBL] [Abstract] [Full Text] [Related]
20. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract] [Full Text] [Related]
[Next]
